Eli Lilly's experimental obesity drug retatrutide successfully met its primary goals in a large diabetes trial, according to BioPharma Dive. The treatment significantly reduced both blood sugar levels and body weight in patients, positioning it as a potential advancement over current GLP-1 drugs like Lilly's own Zepbound.
Retatrutide represents a three-pronged approach to treating obesity and diabetes, though specific clinical data from the trial were not detailed in the available reporting. The drug's ability to simultaneously address blood sugar control and weight reduction suggests it could offer advantages over existing treatments in the competitive obesity drug market.